Light-Activated gel shows promise for psoriasis in early trial
NCT ID NCT05442190
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study tested a gel called SGX302, which is activated by visible light, on 15 people with mild-to-moderate plaque psoriasis. The goal was to see if it could clear or nearly clear skin lesions over 18 weeks. The treatment is applied to the skin and then exposed to light, aiming to control the disease without long-term medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Therapeutics Clinical Research
San Diego, California, 92123, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection clear psoriasis when other biologics fail?
- Can a gel tame psoriasis? new antibody fragment put to the test
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?